MyFinsight
Home
Compare
About
Recent SEC Filings
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Income Overview
Net Income
-$5,785,807
EPS
-$0.54
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-07-31
2026-04-30
2026-01-31
2025-10-31
Revenue
0
0
0
0
Research and development costs
60,000
61,946
93,113
141,085
Intangible asset impairment
-
1,549,427
-
-
General and administrative
946,708
899,882
2,024,989
1,234,966
Total operating expenses
1,006,708
2,511,255
2,118,102
1,376,051
Loss from operations
-1,006,708
-2,511,255
-2,118,102
-1,376,051
Interest income
166,278
78,503
230,668
206,387
Dividend income
240,884
95,170.5*
-
-
Change in fair value of warrant liability
4,221,000
3,589,000
1,895,865
-10,474,000
Change in fair value of derivative liability
597,000
258,000
557,000
302,000
Change in fair value of convertible note receivable femasys
0
0
0
392,000
Change in fair value of warrant asset femasys
-414,000
-426,000
-214,000
-726,000
Change in fair value of investment qcls
-5,550,000
-6,763,000*
1,725,000
-2,371,000
Change in fair value of warrant assets qcls
-3,181,000
1,724,235*
-1,200,000
6,050,000
Loss on related party investment qcls
-
-1,044,500*
0
2,089,000
Gain on legal settlement re-fair value of warrants
0
0
0
0
Issuance costs series c convertible preferred stock and warrants
-
617,276.5*
0
-1,234,553
Loss on legal settlement
-
0*
-
-
Gain on issuance of series c preferred stock
-
107,500*
0
-215,000
Unrealized loss on marketable securities
-154,548
-118,241
-128,939
-60,663
Other expense, net
-97
-132
-632
-95
Total other income (expense), net
-4,074,483
-1,882,188
2,864,962
-6,041,924
Income tax benefit (expense)
0
0
-
-
Net loss
-5,081,191
-4,393,443
746,860
-7,417,975
Preferred stock dividends
83,399
83,399
98,458
96,639
Undistributed income to series b convertible preferred stock
-
0
-
-
Preferred stock accretion
621,217
396,569
2,204,657
901,996
Net loss attributable to common stockholders
-5,785,807
-4,873,411
-1,556,255
-8,416,610
Basic EPS
-0.54
-0.457
-0.17
-1.24
Diluted EPS
-0.54
-0.457
-0.17
-1.24
Basic Average Shares
10,735,649
10,658,777
9,262,829
6,795,779
Diluted Average Shares
10,735,649
10,658,777
9,262,829
6,795,779
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
PMCB Income Statement Sankey Diagram
Sankey diagram visualizing PMCB income statement for the period
Net loss
attributable to common...
-$5,785,807
(30.79%↑ Y/Y)
Net loss
-$5,081,191
(39.22%↑ Y/Y)
Preferred stock accretion
$621,217
Preferred stock dividends
$83,399
Total other income
(expense), net
-$4,074,483
(45.76%↑ Y/Y)
Loss from operations
-$1,006,708
(-18.67%↓ Y/Y)
Change in fair value of
warrant liability
$4,221,000
(1637.04%↑ Y/Y)
Change in fair value of
derivative liability
$597,000
Dividend income
$240,884
Interest income
$166,278
(-23.65%↓ Y/Y)
Change in fair value of
investment qcls
-$5,550,000
Total operating
expenses
$1,006,708
(18.67%↑ Y/Y)
Change in fair value of
warrant assets qcls
-$3,181,000
Change in fair value of
warrant asset femasys
-$414,000
(65.93%↑ Y/Y)
Unrealized loss on
marketable securities
-$154,548
(-47.95%↓ Y/Y)
Other expense, net
-$97
(19.83%↑ Y/Y)
General and
administrative
$946,708
(25.70%↑ Y/Y)
Research and development
costs
$60,000
(-36.95%↓ Y/Y)
Buy us a coffee
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. (PMCB)